Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Bushinsky

Showing results (101-110 of 128) with videos related to

Pageof 13
Sort By:
The New England Journal of Medicine|November 22, 2014
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitorsMatthew R Weir, George L Bakris, David A Bushinsky, et al.
Kidney International Reports|December 11, 2020
Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis - Subgroup Analyses of the CALIPSO TrialPaolo Raggi, Antonio Bellasi, Smeeta Sinha, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 9, 2021
Effects of Myo-inositol Hexaphosphate (SNF472) on Bone Mineral Density in Patients Receiving Hemodialysis: An Analysis of the Randomized, Placebo-Controlled CaLIPSO StudyDavid A Bushinsky, Paolo Raggi, Jordi Bover, et al.
Journal of the American Society of Nephrology : JASN|June 24, 2003
Quantitative trait loci for hypercalciuria in a rat model of kidney stone diseaseRichard R Hoopes, Robert Reid, Saunak Sen, et al.
Nephron|February 7, 2019
Low Sodium Diet Decreases Stone Formation in Genetic Hypercalciuric Stone-Forming RatsNancy S Krieger, Marc Grynpas, Amy VandenEynde, et al.
Journal of the American Society of Nephrology : JASN|May 19, 2019
Chlorthalidone Is Superior to Potassium Citrate in Reducing Calcium Phosphate Stones and Increasing Bone Quality in Hypercalciuric Stone-Forming RatsNancy S Krieger, John R Asplin, Ignacio Granja, et al.
American Journal of Nephrology|December 20, 2015
Treatment of Secondary Hyperparathyroidism: Results of a Phase 2 Trial Evaluating an Intravenous Peptide Agonist of the Calcium-Sensing ReceptorDavid A Bushinsky, Geoffrey A Block, Kevin J Martin, et al.
ESC Heart Failure|May 17, 2018
Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DNBertram Pitt, George L Bakris, Matthew R Weir, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 17, 2019
ErratumDavid A Bushinsky, Glenn M Chertow, Sunfa Cheng, et al.
Kidney International|September 17, 2015
Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemiaDavid A Bushinsky, Gordon H Williams, Bertram Pitt, et al.
Pageof 13

Showing results (101-110 of 128) with videos related to

Sort By:
Pageof 13
The New England Journal of Medicine|November 22, 2014
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitorsMatthew R Weir, George L Bakris, David A Bushinsky, et al.
Kidney International Reports|December 11, 2020
Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis - Subgroup Analyses of the CALIPSO TrialPaolo Raggi, Antonio Bellasi, Smeeta Sinha, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 9, 2021
Effects of Myo-inositol Hexaphosphate (SNF472) on Bone Mineral Density in Patients Receiving Hemodialysis: An Analysis of the Randomized, Placebo-Controlled CaLIPSO StudyDavid A Bushinsky, Paolo Raggi, Jordi Bover, et al.
Journal of the American Society of Nephrology : JASN|June 24, 2003
Quantitative trait loci for hypercalciuria in a rat model of kidney stone diseaseRichard R Hoopes, Robert Reid, Saunak Sen, et al.
Nephron|February 7, 2019
Low Sodium Diet Decreases Stone Formation in Genetic Hypercalciuric Stone-Forming RatsNancy S Krieger, Marc Grynpas, Amy VandenEynde, et al.
Journal of the American Society of Nephrology : JASN|May 19, 2019
Chlorthalidone Is Superior to Potassium Citrate in Reducing Calcium Phosphate Stones and Increasing Bone Quality in Hypercalciuric Stone-Forming RatsNancy S Krieger, John R Asplin, Ignacio Granja, et al.
American Journal of Nephrology|December 20, 2015
Treatment of Secondary Hyperparathyroidism: Results of a Phase 2 Trial Evaluating an Intravenous Peptide Agonist of the Calcium-Sensing ReceptorDavid A Bushinsky, Geoffrey A Block, Kevin J Martin, et al.
ESC Heart Failure|May 17, 2018
Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DNBertram Pitt, George L Bakris, Matthew R Weir, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 17, 2019
ErratumDavid A Bushinsky, Glenn M Chertow, Sunfa Cheng, et al.
Kidney International|September 17, 2015
Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemiaDavid A Bushinsky, Gordon H Williams, Bertram Pitt, et al.
Pageof 13